中

Hot產(chǎn)品

No information

Shenzhen and Hong Kong work together to draw a new blueprint for cross-border medicine- -Dr. Su Jieying, network director of Hong Kong Hospital Authority and Hong Kong Island East Hospital, visited Sh

On September 7 morning, the Hong Kong hospital authority, Hong Kong island east hospital network director Su Jieying doctor, Hong Kong island east hospital networking clinical pathology department manager Zheng Yuhua doctor, administrative manager, medical engineer Mr Dai Zhihua and east of the dozen of hospital clinical oncology department director Dr Song Song communication line to Shenzhen cell valley. Professor Shi Genyuan, chairman of our company, Professor Wang Jianxun, chief scientist, Mr.Zhou Zhaobin, —— Cell Valley (Hong Kong), a Hong Kong subsidiary Holding Company, Wei Zheng, assistant to the chairman, and Sun Rui, minister of Marketing Department warmly received the company.

Under the guidance of Chairman Shi Yuan, the visitor group visited the digital wisdom exhibition hall, GMP RESEARCH and development and production laboratory and quality management laboratory of Shenzhen Cell Valley, and learned about the latest research results and laboratory layout in the field of cell therapy in Shenzhen Cell Valley.

In the following symposium, Chairman Shi Yuanyuan comprehensively introduced the strategic planning, core technology and research and development team of Shenzhen Cell Valley. The chairman of the association stressed that according to the strategic development plan, Shenzhen Cell Valley has set up a subsidiary —— Cell Valley (Hong Kong) holding Company in Hong Kong, which marks the significant progress made in the strategic deployment of Cell Valley this year. In addition, recently, the R & D team of Shenzhen Cell Valley cooperated with the medical team of the city's public third-class hospital, and published the first clinical cure case of CAR T cells for BCMA target for advanced multiple myeloma in an international well-known journal. This case reveals that the clinical grade cell products produced by Shenzhen Cell Valley have high yield, low cost and efficient transfection and in vivo amplification, and it is because of these significant advantages that have won high recognition from doctors.

Su Jieying doctor of Shenzhen cell valley of strategic development planning, master the core technology and clinical case expressed a high degree of recognition, and introduce the island east hospital network is managed by the Hong Kong hospital administration, medical authority implement unified administrative and service management system, establish a unified clinical operation specification, and integrate with international standards. The connected service covers the East District, Wan Chai and the outlying islands, serving about 800,000 people, accounting for 12% of Hong Kong's population. Among them, Mrs.You Hospital is one of the hospitals connected to Hong Kong Island East Hospital, mainly undertaking the regional emergency hospital function of providing comprehensive specialized services. Given the aging population trends and the continued growth in the number of people living with chronic diseases, the medical sector is facing unprecedented challenges, Dr. Su said. She hopes that through in-depth cooperation with Shenzhen Cell Valley in scientific research projects and clinical applications, the Hong Kong Island East Hospital Network can introduce more advanced cell therapy technology, so as to provide more accurate and effective treatment plans for patients.
At the end of the symposium, the two sides reached a consensus that the resource sharing platform between Hong Kong and Shenzhen will jointly promote the development of Shenzhen and Hong Kong in the field of cell therapy, so as to provide better services to the residents of both places.

Previous：Shenzhen Cell Valley was invited to attend the BIOHK2024 Hong Kong Biotechnology Forum and Exhibition

Next：Professor Shi Yuanyuan of our company participated in the formulation of the Comprehensive Diagnosis and Treatment Guidelines of intestinal Microecological Technology for Tumor application in China (2

About Us

Official WeChat Account

Contact Us

400-800-1266

Contact：Miss Sun

Mobile：+86 18810616095

Email：sunrui@sz-cell.com

Address：No.1 Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen

Bottom Navigation

Shenzhen Cell Valley Bio-pharmaceutical Co., Ltd. is a one-stop comprehensive outsourcing service providerfocusing on the cell and gene therapy industry in China, and also the only CRO / CDMO company with the industrial production of clinical grade retroviral carrier GMP. Shenzhen Cell Valley with standardized, industrialized production capabilities.It mainly includes production lines for CAR-T, CAR-NK, CAR-M, mesenchymal stem cells, and astrocytes, as well as several cell raw material production lines, including genetically engineered antibodies, cytokines, exosomes, and viral vectors.Which including retroviral vectors, lentiviral vectors, adenoviral vectors, and adeno-associated viral vectors, and also provides IIT and IND application support services.

Shenzhen Cell Valley Biomedical Co., Ltd Copyright 粵ICP備2023000089號(hào) 客戶隱私和保密條款

国产熟妇另类久久久久,久久99国产精品久久99,好爽好黄好刺激的视频,无码专区国产精品视频

Hot產(chǎn)品

Shenzhen and Hong Kong work together to draw a new blueprint for cross-border medicine- -Dr. Su Jieying, network director of Hong Kong Hospital Authority and Hong Kong Island East Hospital, visited Sh